Osaka, Japan, June 28, 2017 – Takeda Pharmaceutical Company Limited today announced new assignment of Directors. The details are as follows;
1. New assignment of Non-Audit and Supervisory Committee Directors effective June 28, 2017;
|
Name |
Category |
Role |
|
Christophe Weber |
Existing |
Representative Director, President & Chief Executive Officer |
|
Masato Iwasaki |
Existing |
Director, President, Japan Pharma Business Unit |
|
James Kehoe |
New |
Director, Chief Financial Officer |
|
Andrew Plump |
Existing |
Director, Chief Medical & Scientific Officer |
|
Masahiro Sakane |
Existing |
External Director |
|
Yoshiaki Fujimori |
Existing |
External Director |
|
Emiko Higashi |
Existing |
External Director |
|
Michel Orsinger |
Existing |
External Director |
|
Toshiyuki Shiga |
Existing |
External Director |
Masahiro Sakane, an External Director, will chair the board meeting.
2. Audit and Supervisory Committee Directors ;
|
Name |
Role |
|
Yasuhiko Yamanaka |
Director, Audit & Supervisory Committee member |
|
Shiro Kuniya |
External Director, Chairperson of Audit & Supervisory Committee |
|
Koji Hatsukawa |
External Director, Audit & Supervisory Committee member |
|
Jean-Luc Butel |
External Director, Audit & Supervisory Committee member |
Audit and Supervisory Committee Directors are within their 2-year tenure, and were not subjects for reelection this year.
3. New assignment of Non-Audit and Supervisory Committee Directors effective June 28, 2017;
- Compensation committee : Toshiyuki Shiga (Chair), Yoshiaki Fujimori, Yasuhiko Yamanaka
- Nomination committee : Masahiro Sakane (Chair), Emiko Higashi,
Shiro Kuniya, Christophe Weber
Media Contact
Kazumi Kobayashi
Tel: +81-3-3278-2095
Email: [email protected]
###